Table 4 Comparison of the medications during discharge and follow-up between patients who had emergency left main (LM) vs. non-emergency LM revascularization
|  | Overall, n = 2138 | Emergent LM revascularization n = 460 (21.5%) | P-Value | Non-emergent LM revascularization n = 1678 (78.5%) | P Value | ||
|---|---|---|---|---|---|---|---|
PCI (n = 264) | CABG (n = 196) | PCI (n = 958) | CABG (n = 720) | ||||
Discharge medications | |||||||
 ASA, n (%) | 2010 (99.10%) | 222 (99.55%) | 166 (97.65%) | 0.095 | 946 (99.58%) | 676 (98.69%) | 0.045 |
 P2Y12 inhibitors, n (%) | 1833 (90.40%) | 223 (100%) | 129 (75.88%) |  < 0.001 | 946 (99.58%) | 535 (78.10%) |  < 0.001 |
 Beta blocker, n (%) | 1914 (94.40%) | 216 (96.86%) | 146 (85.88%) |  < 0.001 | 915 (96.32%) | 637 (92.99%) | 0.003 |
 Statin, n (%) | 1934 (95.40%) | 214 (95.96%) | 139 (81.76%) |  < 0.001 | 947 (99.68%) | 634 (92.55%) |  < 0.001 |
 ACE inhibitors or ARB, n (%) | 1516 (74.80%) | 202 (90.58%) | 86 (50.59%) |  < 0.001 | 847 (89.16%) | 381 (55.62%) |  < 0.001 |
Medications during follow-up | |||||||
 ASA, n (%) | 1713 (97.10%) | 174 (96.67%) | 135 (100%) | 0.032 | 859 (97.50%) | 545 (95.78%) | 0.068 |
 P2Y12 inhibitors, n (%) | 1129 (64.00%) | 140 (77.78%) | 83 (61.48%) | 0.002 | 638 (72.42%) | 268 (47.10%) |  < 0.001 |
 Beta blocker, n (%) | 1674 (94.80%) | 171 (95.00%) | 129 (95.56%) | 0.819 | 838 (95.12%) | 536 (94.20%) | 0.443 |
 Statin, n (%) | 1727 (97.80%) | 174 (96.67%) | 130 (96.30%) | 0.859 | 873 (99.09%) | 550 (96.66%) | 0.001 |
 ACE inhibitors or ARB, n (%) | 1332 (75.50%) | 159 (88.33%) | 71 (52.59%) |  < 0.001 | 765 (86.83%) | 337 (59.23%) |  < 0.001 |